The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.
Oliver Klein
No relevant relationships to disclose
Ian D. Davis
No relevant relationships to disclose
Grant A. McArthur
No relevant relationships to disclose
Andrew Mark Haydon
No relevant relationships to disclose
Phillip Parente
No relevant relationships to disclose
Nektaria Dimopoulos
No relevant relationships to disclose
Heather Jackson
No relevant relationships to disclose
Eugene Maraskovsky
Employment or Leadership Position - CSL Limited
Stock Ownership - CSL Limited
Other Remuneration - CSL Limited
Wendie Hopkins
No relevant relationships to disclose
Rodica Stan
No relevant relationships to disclose
Weisan Chen
No relevant relationships to disclose
Jonathan S. Cebon
No relevant relationships to disclose